cbp-4888
Nucleic acidexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 22, 2023 (NCT05881993)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Vascular endothelial growth factor receptor 1ANTISENSE INHIBITOR
FLT1 antisense inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07282171 | Phase 1 | Dec 31, 2025 | Comanche Biopharma |
| NCT05881993 | Early Phase 1 (Phase 1) | May 22, 2023 | Comanche Biopharma, University of California, San Francisco |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Comanche Biopharma | For profit | 2 | 2 | 1 | 2023 |
| University of California, San Francisco | Academic/Hospital | 1 | 0 | 1 | 2023 |
2 organizations
Page 1 / 1